FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2

Arcutis Biotherapeutics (ARQT) achieved a significant regulatory milestone with FDA approval of ZORYVE for pediatric plaque psoriasis patients aged 2 and above. This represents the company's seventh approval for the roflumilast cream formulation within four years, demonstrating sustained regulatory momentum and label expansion momentum in the dermatology segment.

The pediatric indication carries meaningful commercial value as it opens a previously underserved patient population with chronic inflammatory skin conditions. The non-steroidal, once-daily formulation with unrestricted duration of use addresses a clinical gap, potentially positioning ZORYVE as a first-line therapy in pediatric settings. This approval expands the addressable market beyond adult populations and strengthens competitive positioning against steroid-based alternatives.

The sequence of seven regulatory approvals in four years signals robust clinical efficacy and safety profiles supporting multiple indication extensions. This velocity of approvals typically reflects strong institutional confidence and suggests additional pipeline depth within the immuno-dermatology franchise. The pediatric label expansion is particularly strategically valuable given the chronic nature of psoriasis and potential for long-term patient relationships.

Sector implication: This approval is accretive to Health Care sector sentiment, particularly specialty pharmaceuticals and immuno-dermatology segments. Successful pediatric approvals drive durable revenue streams and create differentiation in competitive therapeutic areas. The regulatory pattern underscores ARQT's execution capability in clinical development and regulatory strategy.